Wistar Earns ‘Exceptional’ Rating for NCI Cancer Center Support Grant for the Second Review Cycle in a Row, Demonstrating Strength of Science

The Wistar Institute’s Cancer Center has received an “exceptional” rating on its Cancer Center Support Grant (CCSG) application from the National Cancer Institute (NCI) for the second review cycle in a row and the grant has been recommended...
23-Apr-2019 10:00 AM EDT Add to Favorites

Synthetic DNA-encoded Antibodies Against Zika Virus Shown to be Effective in Preclinical Studies

New approach for delivery of DNA-encoded monoclonal antibodies (DMAbs) has been reported by Wistar scientists. This new technology allows direct production of monoclonal antibody-like molecules in living animals.
5-Apr-2019 11:05 AM EDT Add to Favorites

New Small Molecule Inhibitors Show Potential for Treatment of Epstein-Barr Virus-Associated Cancers

Researchers at The Wistar Institute have created a drug candidate for cancers associated with Epstein-Barr Virus (EBV), the virus that causes infectious mononucleosis.
5-Mar-2019 10:40 AM EST Add to Favorites

New Insight Into the Balance Between the Tumor-suppressive and Tumor-promoting Effects of Cellular Senescence

Researchers at The Wistar Institute have described a novel role of nicotinamide adenine dinucleotide (NAD+) metabolism in the ability of senescent cells to release tumor-promoting molecules.
18-Feb-2019 11:00 AM EST Add to Favorites

Combination of T Cell Therapy and Targeted Therapy as a Novel Strategy for Therapy-resistant Melanoma with Mutations in the BRAF Gene

Collaborative research by The Wistar Institute and Moffitt Cancer Center has demonstrated that BRAF targeted therapies render resistant melanoma more sensitive to the attack of killer T cells.
14-Feb-2019 10:00 AM EST Add to Favorites

Federal Funding Fueled Growth of Wistar Science in 2018

The Wistar Institute announces that it was awarded more than $16M in federal research funds in support of its groundbreaking research in cancer, immunology and infectious diseases.
11-Feb-2019 11:00 AM EST Add to Favorites

Engineered DNA Vaccine Protects Against Emerging Mayaro Virus Infection

A novel, synthetic DNA vaccine developed at The Wistar Institute induces protective immunity against Mayaro virus (MAYV), a mosquito-borne infection endemic to South America, that has the potential to become a global emerging viral threat.
5-Feb-2019 4:10 PM EST Add to Favorites

Induction of Potent Anticancer Immunity Through Rapid Tumor Antigen Identification and Conversion to Personalized Synthetic DNA Vaccines

Wistar scientists and collaborators demonstrated the utility of an optimized synthetic DNA vaccine platform for rapidly inducing immunity against unique combinations of tumor neoantigens.
22-Jan-2019 4:30 PM EST Add to Favorites

see all news